4-Hydroxytamoxifen (Afimoxifene) vs Enclomiphene

Hormone

Hormone

Research Only

Research Only

Afimoxifene is a competitive antagonist/partial agonist at estrogen receptors alpha and beta, exhibiting tissue-selective activity characteristic of SERMs. Receptor-binding studies on estrogen receptors isolated from human breast carcinoma found 4-hydroxytamoxifen binds ER with affinity equal to estradiol and 25–50× higher than tamoxifen itself, which is why it is considered tamoxifen's principal active metabolite despite low circulating abundance (2–18% of parent drug). Unlike tamoxifen and endoxifen, whose formation depends on hepatic CYP2D6/CYP3A4 activity, 4-hydroxytamoxifen is already the pharmacologically active hydroxylated species, which is the rationale for delivering it directly (e.g., as a topical gel) to bypass variable CYP2D6-dependent bioactivation of oral tamoxifen.

Enclomiphene blocks estrogen receptors at the hypothalamus, disinhibiting GnRH pulse generation. The resulting rise in LH and FSH stimulates testicular Leydig-cell testosterone production and Sertoli-cell spermatogenesis. Because it lacks the estrogenic zuclomiphene component and is not exogenous testosterone, it raises endogenous T without suppressing gonadotropins or intratesticular testosterone.

Approximately 10-14 hours